TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2017

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.

Dae Hyun Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.